A randomised controlled trial of raw honey for the healing of ulcers in leprosy in Nigeria Authors: Paul Alumbugu Tsaku, Sunday Odihiri Udo, Pius Sunday, Anthony Meka, Linda Chinonso Ugwu, Abiola Oladejo, Joshua Akinyemi, Akinyinka Omigbodun, Sopna Choudhury, Jo Sartori, Onaedo Ilozumba, Samuel Watson, Richard Lilford, Ana LTO Nascimento, Ana LTO Nascimento, Ana LTO Nascimento Published: 2025 ABSTRACT IntroductionChronic neuropathic ulcers remain a debilitating complication of leprosy, with limited evidence for effective treatments. Honey has been recommended to promote wound healing in other chronic ulcers. However, its efficacy in ulcer healing has not been rigorously evaluated.MethodsThis dual-centre, prospective, single-blinded, randomised controlled trial compared raw honey dressings (n = 65) versus standard saline dressings (n = 65) for leprosy-associated foot ulcers in Nigeria. Participants with ulcers (2–20 cm2, ≥ 6 weeks duration) were randomised 1:1, stratified by ulcer size. Primary outcomes were complete healing by 84 days and healing rate, assessed through blinded digital planimetry. Secondary outcomes included ulcer recurrence and/or new ulcer development at 6 months. A total of 130 participants were randomised in the study.ResultsComplete healing occurred in 29.2% of honey-treated ulcers versus 24.6% with saline (adjusted HR 1.26, 95% CI 0.64-2.47). At 6 months, recurrence rates were similar (honey 13.5% vs saline 10.2%). The honey group showed a non-significant trend toward faster healing (p = 0.076). No treatment-related adverse events occurred.ConclusionWhile honey dressings showed a modest advantage in healing rate, the difference was not statistically significant. The results suggest honey may be a safe, culturally acceptable option in resource-limited settings. This study provides high-quality data for inclusion in future systematic reviews.Trial registrationISRCTN10093277. Registered on 22 December 2021. Introduction In leprosy, ulcers result from repeated trauma due to nerve impairment and sensory loss [1,2]. Nerve impairment results from both the direct effects of the causative organism, Mycobacterium leprae (M. leprae) complex in the peripheral nerves, and the host’s immune response to it, leading to inflammation and demyelination in peripheral nerves [3,4]. As with diabetes and other causes of neuropathy, the combination of loss of sensation and deformities leads to chronic, recalcitrant, and recurring ulcers. It is estimated that 30 – 50% of people affected by leprosy eventually develop foot ulcers [5,6]. There has been recent advocacy for high-quality research on ulcer treatment and prevention in leprosy, specifically advocating for randomised controlled trials (RCTs) [7]. Being a Neglected Tropical Disease (NTD), there is a paucity of documentation on the management of leprosy, especially on the treatment of ulcers. Traditionally, the management of leprosy ulcers involves the regular soaking of the affected area in water and the use of paraffin oil for debridement and to promote self-healing. This practice constitutes what is termed ‘self-care’ in leprosy [8,9]. Additional methods to promote healing include leukocyte and platelet-rich fibrin (L-PRF) [6], biomaterials [10], and removable offloading devices, but none of these have been proven to be effective [11,12]. In this study, we conducted a randomised controlled trial of raw African honey for the healing of ulcers in leprosy. The use of honey as a therapeutic agent in the treatment of wounds is an ancient practice, with the earliest documented report recorded in the Edwin Smith papyrus (2600 – 2200 BCE). Honey is a viscous, supersaturated solution containing sugars, water, amino acids, vitamins, minerals, enzymes, and many other substances derived from nectar gathered and modified by the honeybee, Apis mellifera [13,14]. Studies have shown that honey promotes wound healing, stimulates tissue growth, facilitates debridement and epithelization, reduces odurs, reduces oedema and exudates, and possesses antimicrobial properties [15–17]. Currently, there is a lack of scientific evidence on the use of honey for the treatment of leprosy ulcers. A recent Cochrane systematic review has reported several studies with unclear outcomes for trials with honey on venous leg ulcers, diabetic foot ulcers, and mixed chronic wounds [7]. The review concludes that most of the reported studies were of low quality with a high risk of bias due to non-blinding of observers, and statistical heterogeneity was evident across studies. Methods Ethics statement The study protocol was approved by the National Health Research Ethics Committee in Abuja (Ref: FHREC/2022/01/09/04-02-22); the University of Nigeria Teaching Hospital in South East Nigeria (Ref: UNTH/HREC/2023/01/504); and the University of Birmingham (Ref: ERN_21–1388). Informed consent was obtained from all participants following a detailed explanation of the study procedures. Each participant received an information sheet and was given at least 24 hours to consider their involvement before providing written consent. Additionally, indemnity insurance was secured for all participants to ensure coverage in the event of any serious adverse occurrences related to study participation. Trial design This was a dual-centre, prospective, single-blinded, parallel-group, 1:1 individually randomised controlled trial. The study duration was 29 months (March 2022 – August 2024), including post-discharge follow-up at 6 months after randomisation. The trial was registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry, with the number: ISRCTN10093277 (https://www.isrctn.com/ Registered on 22 December 2021). The study protocol has also been published [18]. The study pathway is shown in Fig 1. The Pathway for recruitment of participants into the study. Study setting The study centres are The Leprosy Referral Hospital, Chanchaga, Minna, Niger State, in North-central Nigeria, and St. Benedict Tuberculosis and Leprosy Relief Hospital, Ogoja, Cross River State, in South-south Nigeria. The Leprosy Referral Hospital, Chanchaga is a specialist hospital operated by the government of Niger state with support from The Leprosy Mission Nigeria, while the St Benedict Tuberculosis and Leprosy Relief Hospital, Ogoja is a TB and leprosy referral hospital located in Ogoja, a town in the northern part of Cross River State of Nigeria, owned by the Catholic church in Cross River State, Nigeria, with the technical support from Red-Aid Nigeria formerly the German Leprosy and TB Relief Association (DAHW). The sites were selected for their specialization in leprosy care, established partnerships with the research team (The Leprosy Mission Nigeria and RedAid-Nigeria), and geographic diversity (north-central vs. south-south Nigeria) to enhance generalisability. Eligibility criteria (patients and ulcers) Eligible participants for inclusion in the study met the following criteria: i. Patients with a chronic foot ulcer of at least 6 weeks duration due to leprosy neuropathy. i. Patients with a chronic foot ulcer of at least 6 weeks duration due to leprosy neuropathy. ii. ≥ 18 years of age. ii. ≥ 18 years of age. iii. Ulcer surface area between 2 and 20 cm2. iii. Ulcer surface area between 2 and 20 cm2. iv. Ulcer is clean, dry, and free from infection. iv. Ulcer is clean, dry, and free from infection. v. The patients who can/and have signed the informed consent forms. v. The patients who can/and have signed the informed consent forms. Those that failed to meet the inclusion criteria were excluded from participation in the study. In scenarios where a participant has more than one foot ulcer, the largest ulcer that falls between 2 and 20 cm2 was selected as the index ulcer before randomisation, and all other ulcers were treated in the standard way. Informed consent Researchers at the study centres were trained on Good Clinical Practice (GCP) and were responsible for obtaining consent from the study participants. They also screened the participants for eligibility before obtaining written informed consent. The participants’ information sheet was translated into the local language (Hausa). All relevant information for the research participants in the study was contained in the participants’ information sheet. The information sheet was handed to the participants a day before enrolment into the study. A copy of the information sheet used and the consent form are included as supplementary materials (S1 and S2 Texts). The intervention The intervention used for this study was raw, unadulterated honey obtained from local bee farmers in Nigeria. The honey samples were examined at the National Institute for Pharmaceutical Research and Development (NIPRD), Abuja, and confirmed to be free from Microbial contaminants. The honey was applied topically to the wound during dressing under strict hygienic conditions using sterilised equipment. The treatment was twice-weekly dressings conducted by nurses or paramedics. The control The participants in the control group received the usual care of twice-weekly normal saline dressings only. The normal saline dressing is the standard ulcer dressing method currently in use in the hospitals where the trial took place. Tracking of steps In line with standard practice, participants were discouraged from bearing weight on the ulcer site since weight bearing and the level of activity of patients might affect the rate of healing of the ulcers. Participants were asked to wear pedometers on the non-affected foot, and the step counts were recorded at each dressing change from the first dressing change until 84 days from randomisation or discharge, whichever came first. Discharge The trial participants were discharged at 84 days after randomisation or when healing (complete re-epithelialization) occurred before the 84th day of hospitalisation. The date of discharge was noted along with the participants’ contact details, address, and contact details of at least one family member. Follow-up The participants were contacted six months after randomisation for follow-up, during which the treated ulcer area was examined and photographed. The treated ulcer area is also examined for recurrence or the presence of any new ulcers. Sample size A total of 130 participants were enrolled in the study. The sample size was chosen based on the two clinical outcomes: rate of healing and time to complete re-epithelialization. We anticipated that 70% of ulcers would heal within 84 days with standard care (according to a recent study of neuropathic ulcers, over half due to leprosy [19]). In that case, we assumed that the intervention would increase this proportion to 90% and hazards are constant and proportional (so that the hazard ratio is 1.91 for discharge), for a two-sided test of the hazard ratio with a type I error of 5% and statistical power of 80% and a 1:1 allocation ratio, 47 individuals are required in each group. With 130 participants, this allows for a dropout rate of up to 40% to achieve the power of 80%. At the most pessimistic sample size of 90, with a dropout rate of 40%, our minimum detectable effect size (i.e., the effect size that achieves an 80% power with 33 patients per arm) is a hazard ratio of 2.15, or 92.5% of patients in the treatment group being discharged by the end of the trial period. At the most optimistic sample size of 130 with no dropout, our minimum detectable effect size is a hazard ratio of 1.74, or 87.3% of patients being discharged in the treatment group. All calculations are based on a log-rank test. We take a conservative approach and base the sample size calculation on the healing outcome and model with lower efficiency to ensure an adequate sample size for all main outcomes, since our inferential approach is not based on statistical significance but on a consideration of effect sizes and a comparison and triangulation of the totality of evidence. We were not concerned particularly with being “overpowered” or with a problem of multiple comparison (we expect the outcomes to be correlated), but with ensuring a sufficient sample size to estimate clinical effectiveness to a reasonable degree of precision [20,21]. Randomisation and blinding The participants were enrolled sequentially, stratified by ulcer size (above or below 10 cm2), and randomly allocated (1:1) to undergo honey treatment or usual care with normal saline using a “digital sealed envelope” method [22,23]. An allocation table was generated remotely at the trials office at the University of Ibadan. A permuted block randomisation method was used to generate the randomisation sequence within each stratum. Randomly selecting blocks of size 2, 4, 6, or 8 was generated in order to maintain balance between the numbers allocated to each of the two groups and to ensure allocation concealment. The generated table was uploaded to the REDCap database (https://itm-redcap.bham.ac.uk/) and used for participant enrolment. Access to the allocation table was restricted, and staff in recruiting sites were not given access to the allocation table. When a participant’s details were submitted, the trial arm and a unique study number were assigned and revealed to the local clinician so that the randomised group that the participant is assigned to could not be altered. Only the overall research supervisor on site, the database managers in Birmingham, and the University of Ibadan trials unit, the clinical staff carrying out dressing changes in the room designated for this purpose, and participants themselves were aware of participants’ randomly assigned group. The assessors were blinded to the treatment provided for randomly assigned groups. Data collection As stated under ‘eligibility criteria’, patients were selected on the basis of an ulcer of 2–20 cm. We obtained standardised photographs of the index ulcers (see eligibility criteria) twice weekly during dressing changes for all participants [23]. The photographs were taken using the built-in camera in the tablet devices (Samsung Galaxy Tab S7, 13MP). The photographs were taken perpendicular to the ulcer. For calibration purposes, a 3 cm size clean paper ruler with date and participant’s trial identification number was placed in the photograph frame below the ulcer, but at the level of the skin. The photographs were then uploaded into the REDCap database and accessed by database managers at the University of Birmingham. The ulcer photos were then randomised and sent to the blinded assessors in Nepal for measurement of ulcer dimensions. The photographs were evaluated digitally by the designated observer in Nepal using the PictZar Digital Planimetry Software with an electronic PUSH Tool (National Pressure Injury Advisory Panel (NPIAP) at https://npiap.com/page/PUSHTool). This tool is a validated method for wound measurement with high intra- and inter-observer reliability (ICC > 0.95) [24–26]. The observers delineated an area of interest by manually ‘painting’ the ulcer area with colour using a computer mouse. The software then calculated the ulcer dimensions based on this profile. We collected data on age, gender, height, weight (and hence Body Mass Index), the anatomical position of the ulcer, a composite test of neurological (motion and sensory) functioning – the Voluntary Muscle Testing and Semmes-Weinstein monofilament testing (VMT/SWMT), which is dichotomised into normal or impaired. Data management All data generated from this study are classified according to the University of Birmingham Information Security Framework. All data were collected and stored electronically to reduce data entry errors, such as contradicting answers. Data was reported on an electronic Case Report Form (eCRF), and all local staff were trained to collect data directly onto electronic tablets. The data was stored on the REDCap database platform with access restricted by passwords at both the University of Ibadan and the local site in Nigeria. Each participant was allocated a unique study number when they agreed to participate (and before randomisation), which was used on all documents. A master list linking a trial participant number to their identity (name) was retained by the hospital securely in a locked filing cabinet. Statistical analysis The primary analysis is the adjusted Cox proportional hazards model for time to complete healing (our key primary outcome), as this accounts for prognostic baseline factors (ulcer size and age) per standard practice in survival analyses for wound healing trials. All analyses are conducted on an intention-to-treat (ITT) basis, including all randomised participants with available outcome data (right-censored for non-healers at 84 days), consistent with CONSORT guidelines and the trial protocol. Unadjusted models and the linear mixed-effects analysis for healing rate are presented as supportive/secondary, with no post-hoc adjustments beyond the pre-specified multiple-testing correction (stepdown procedure on the two primary outcomes). For the rate of healing, we define the outcome ulcer size in cm2 at each time point and include in the model time since admission, treatment status, and their interaction. We analysed this model using a linear mixed-effects model with participant-level random effects and both with and without adjustment for participant characteristics. Given there are multiple clinical outcomes (two outcomes, with and without adjustment), we adjusted reported p-values for multiple testing using a stepdown method, which provides an efficient means of controlling the family-wise error rate [22]. We also derived the approximate distributions of the test statistics to perform the stepdown procedure using a permutation test approach, by simulating 10,000 re-randomisations of the individuals [23]. We also compared the average daily step count between treatment and control groups as a simple difference in means (t-test). Since one group may stay longer in hospital than the other and since there may be an interaction between rate of healing and step count, we compared step counts over periods pre-set at 7, 14 and 42 days. An interim analysis was conducted when 49 (three eights of the target) were followed up after discharge. The rationale for this analysis was for the detection of a ‘penicillin-like’ benefit or statistically significant negative effect of the treatment on either primary outcome. A statistical threshold of 0.01, one-sided (0.02 two-sided) was used for either primary outcome. Following the outcome of the interim analysis, the Independent Data Monitoring Committee (IDMC) examined the report and advised the Trial Steering Committee accordingly. Secondary treatment outcomes For the outcomes recorded on the 6-month post-randomisation follow-up questionnaire, their analysis includes participants who provided their responses within 1 month (+/-) of the 6-month post-randomisation time point. To examine the possible impact of the excluded data on the results, sensitivity analyses were performed on the 6-month follow-up outcome measures by including all participants. The secondary outcomes are: Recurrence of treated ulcer at 6 months from randomisation. Recurrence of treated ulcer at 6 months from randomisation. Appearance of a new ulcer at 6 months from randomisation. Appearance of a new ulcer at 6 months from randomisation. Anatomical changes in the limb at 6 months from randomisation. Anatomical changes in the limb at 6 months from randomisation. Oversight and monitoring The Leprosy Mission Nigeria is the study sponsor and oversees the study process in Nigeria. The University of Ibadan provided data management services and performed quality checks, while the University of Birmingham housed the data securely and performed quality checks. The Trial Management Group (TMG) includes individuals at the University of Birmingham, The Leprosy Hospital Chanchaga, The Leprosy Mission Nigeria, RedAid Nigeria and the University of Ibadan Clinical Trials Unit who are responsible for the day-to-day management of the trial. The TMG met monthly by teleconference. The Trial Steering Committee (TSC) provided the overall supervision of the trial and ensured that it was being conducted in accordance with the principles of Good Clinical Practice and other relevant regulations. The TSC kept oversight of the trial. Adverse event reporting and harms The principal investigator in Nigeria is responsible for recording all Adverse Events (AEs) and reporting any Serious Adverse Events (SAEs) to the University of Birmingham and the University of Ibadan within 24 hours of the research staff becoming aware of the event. An SAE Form was made available on the tablets used to collect data and maintain a database of all safety/adverse events. The forms were reviewed by the TMG, which meets monthly and if required, also by the Project Manager. The TSG will periodically review all safety data and liaise with the Independent Data Monitoring Committee regarding any safety issues. Any deaths were reported to the Sponsor irrespective of whether the death was related to the disease progression, the intervention or an unrelated event. Only deaths that could plausibly be caused by the intervention were reported to the Sponsor immediately. Results Screening and recruitment of participants A CONSORT (CONsolidated Standards of Reporting Trials) flow chart showing participant recruitment and progression through the trial is presented in Fig 2. A total of 146 individuals were screened, of whom 130 met the inclusion criteria and were randomised. Sixteen [16] participants were excluded due to not meeting eligibility requirements. The 130 randomised participants were equally allocated to receive either normal saline dressing (n = 65) or honey dressing (n = 65). Throughout the study, 47 participants withdrew or were lost to follow-up at various stages. CONSORT Flow diagram of the study. FU = follow-up. At six months post-randomisation, follow-up was completed for 40 participants in the normal saline group and 43 participants in the honey group. Three participants died after discharge; however, none of the deaths were related to the intervention or study procedures. Baseline characteristics The mean age of participants at recruitment was 50.5 (SD = 15.1) years, with an age range of 18–82 years. The average size of the 130 ulcers at baseline was 9.1 cm2 (SD = 9.7) with a median of 6 cm2 (IQR, 4, 9). A total of 85 males and 45 females were enrolled in the trial. Most participants had no formal education, and only one had attained university-level education. The mean height, weight, and body mass index (BMI) were 162.8 (SD = 8.5) cm, 55.6(SD = 11.9) kg, and 21.0 (SD = 4.2), respectively. On average, participants had been living with leprosy for 21.3 (SD = 16.2) years. The trial ulcers had remained unhealed for a mean duration of 97.1 weeks prior to enrolment. A detailed summary of baseline characteristics is presented in Table 1 below. 10.1371/journal.pntd.0013454.t001Table 1Participant baseline characteristics.Dressing changes with Normal saline(n = 65)Dressing changes with Honey(n = 65)Total(n = 130) Participant demographics Gender, n (%)Male42 (64.6)43 (66.2)85 (65.4)Female23 (35.6)22 (33.9)45 (34.6)Highest level of educationNever joined formal school37 (56.9)40 (61.5)77 (59.2)Primary level17 (26.2)16 (24.6)33 (25.4)Secondary level6 (9.2)4 (6.2)10 (7.7)Higher secondary level4 (6.2)5 (7.7)9 (6.9)University level1 (1.5)0 (0.0)1 (0.8) Clinical information Height in cmMean (SD)162.8 (8.9)162.9 (8.2)162.8 (8.5)Weight in kgMean (SD)55.4 (11.5)55.8 (12.4)55.6 (11.9)BMIMean (SD)20.9 (4.3)21.0 (4.2)21.0 (4.2) VMT/ST VMT/STNormal7 (10.8)3 (4.6)10 (7.7)Impaired58 (89.2)62 (95.4)120 (92.3) Current Ulcer Information Location of the trial ulcerLeft forefoot19 (29.2)25 (38.5)44 (33.9)Left midfoot26 (40.0)15 (23.1)41 (31.5)Left hindfoot7 (10.8)9 (13.9)16 (12.3)Right forefoot7 (10.8)5 (7.7)12 (9.2)Right midfoot4 (6.2)6 (9.2)10 (7.7)Right hindfoot2 (3.1)5 (7.7)7 (5.4) Measurements of the trial ulcer (for eligibility) ǂ Trial ulcer Area (cm2)Mean (SD)8.7 (8.3)9.6 (11.1)9.1 (9.7)Range2, 492, 632, 6Data are either mean (SD) or number (%). Participant baseline characteristics. Data are either mean (SD) or number (%). Treatment outcomes Two main outcome measures were evaluated: (1) the rate of wound healing (‘primary’ outcome), determined by the change in ulcer surface area per unit time based on biweekly measurements (cm2/time), and (2) the duration required for complete re-epithelialization, assessed at the 84-day mark. Fig 3 illustrates a logarithmic trend of ulcer size reduction over time, comparing the efficacy of honey-based dressings with that of normal saline dressings. Both interventions resulted in slow progressive reduction in ulcer size which was slightly faster in the honey group. However, the difference between the two treatments was not statistically significant. Log of ulcer size over time by treatment arm. The analysis of time to achieve healing or complete re-epithelialisation within 84 days post-randomisation is presented in Table 2. The unadjusted hazard ratio (HR) for honey compared to saline was 1.17 (95% CI: 0.60–2.27). The adjusted HR (for ulcer size and age) was 1.26 (95% CI: 0.64–2.47). In both cases, the confidence intervals included 1, indicating no statistically significant difference in healing rates between the two treatments but with a point estimate favoring the intervention. 10.1371/journal.pntd.0013454.t002Table 2Analysis of primary outcome measure - Time to complete re-epithelisation.Time pointDressing changes with Normal saline(n = 65)Dressing changes with Honey(n = 65)Unadjusted Hazard Ratio*(95% CI)AdjustedǂHazard Ratio*(95% CI)Number of participants that withdrew before reached 84 days post randomisation5(7.7%)3 (4.6%)At 84 days after randomisationNumber of Participants that had not reached complete re-epithelisation up to 84 days after randomisation44 (67.7%)43 (66.2%)1.17 (0.60, 2.27)1.26 (0.64, 2.47)Number of Participants that had complete re-epithelisation up to 84 days after randomisation16 (24.6%)19 (29.2%)ǂCox proportional hazards adjusted for the baseline values of trial ulcer size and patient age. Trial ulcer size and patient age was treated as continuous variables and considered as fixed effects in the adjustment. * HR > 1 means – hazard of ‘healing’ is higher in dressing changes with Honey. Analysis of primary outcome measure - Time to complete re-epithelisation. ǂCox proportional hazards adjusted for the baseline values of trial ulcer size and patient age. Trial ulcer size and patient age was treated as continuous variables and considered as fixed effects in the adjustment. * HR > 1 means – hazard of ‘healing’ is higher in dressing changes with Honey. Test of proportional hazard assumption The proportional hazards assumption was tested using Schoenfeld residuals. The global test (p = 0.28) and all covariates (age: p = 0.40; ulcer area: p = 0.65) met the PH assumption. Other outcomes measured are included in the full analysis report attached as supplementary materials (S3 Text). The results for secondary outcomes are presented in Table 3 below, which showed that there was no difference between the arms. 10.1371/journal.pntd.0013454.t003Table 3Analysis of binary secondary outcomes.Dressing changes with normal saline (n = 49)Dressing changes with Honey (n = 52)Adjusted Relative Risk1 (95% CI)Adjusted Risk Differnce2 (95% CI) Recurrence of treated ulcer at 6 months from randomisation Yes5 (10.2%)7 (13.5%)1.34 (0.46, 3.92)0.04 (-0.10, 0.19)No37 (75.5%)37 (71.2%)Missing00Excluded from analysis7 (14.3%)8 (15.4%) Appearance of a new ulcer at 6 months from randomisation Yes2 (4.1%)1 (1.9%)0.33 (0.04, 2.93)–No40 (81.6%)42 (80.8%)Missing01Excluded from analysis78 Anatomical changes in the limb at 6 months from randomisation 6 monthsNormal7 (14.3%)2 (3.9%)1.14 (0.98, 1.32)3Impaired35 (71.4%)42 (80.8%)Missing00Excluded from analysis781: Log-binomial regression model adjusted for the baseline values of trial ulcer size and participant age. Trial ulcer size and participant age were treated as continuous variables and considered as fixed effects in this adjustment. Adjusted RR > 1 means a higher rate of recurrent or new ulcers, respectively, was observed in the dressing changes with the honey group.2: Log-binomial regression model using the identity link function adjusted for the baseline values of trial ulcer size and participant age. Trial ulcer size and participant age were treated as continuous variables and considered as fixed effects in this adjustment. Adjusted RD > 0 means a higher risk of recurrent or new ulcers, respectively, for the dressing changes with the honey group.3: Poisson regression model with robust standard errors adjusted for the baseline values of trial ulcer size and participant age. Trial ulcer size and participant age were treated as continuous variables and considered as fixed effects in this adjustment. Adjusted RR > 1 means a higher rate of normal limb was observed in the dressing changes in the honey group. Analysis of binary secondary outcomes. 1: Log-binomial regression model adjusted for the baseline values of trial ulcer size and participant age. Trial ulcer size and participant age were treated as continuous variables and considered as fixed effects in this adjustment. Adjusted RR > 1 means a higher rate of recurrent or new ulcers, respectively, was observed in the dressing changes with the honey group. 2: Log-binomial regression model using the identity link function adjusted for the baseline values of trial ulcer size and participant age. Trial ulcer size and participant age were treated as continuous variables and considered as fixed effects in this adjustment. Adjusted RD > 0 means a higher risk of recurrent or new ulcers, respectively, for the dressing changes with the honey group. 3: Poisson regression model with robust standard errors adjusted for the baseline values of trial ulcer size and participant age. Trial ulcer size and participant age were treated as continuous variables and considered as fixed effects in this adjustment. Adjusted RR > 1 means a higher rate of normal limb was observed in the dressing changes in the honey group. Step counts Step counts were recorded using pedometers attached to each participant’s foot to quantify activity levels. This method was used to examine the plausibility of ‘performance bias’ whereby patients in the intervention group may reduce weight bearing to a greater extent than patients in the control groups given that weight-bearing may impede the healing process. The analysis compared the number of steps taken by participants in the treatment group versus those in the control group. The results indicated that the difference in mean daily step counts between the two groups was not statistically significant. Step counts collected on days 7, 14, and 42 post-randomisation are presented in Table 4 and are very similar across groups. 10.1371/journal.pntd.0013454.t004Table 4Analyses of activity measurement (step count) at 7, 14, and 42 days post-randomisation.Activity measurementDressing changeswith normal saline(N = 65)Dressing changes with Honey(N = 65)Mean Difference195% CIAverage daily steps measuredat 7 days post randomisationN616179.9(-467.1, 626.9)Mean (SD)1859.6 (1628.4)1779.7 (1415.5)Min - Max0 – 6690.30 – 6263.4Missing44Average daily steps measuredat 14 days post randomisationN566139.0(-540.4, 618.4)Mean (SD)2039.5 (1678.8)2000 (1573.9)Min - Max0 - 69930 - 7002Missing94Average daily steps measuredat 42 days post randomisationN494967.7(-714.8, 850.3)Mean (SD)2381.6 (1817.3)2313.9 (2076.8)Min - Max0 – 6504.10 – 12388.9Missing16161: Mean difference is estimated using a t-test. MD > 0 indicates higher mean daily steps in dressing changes with honey group. Analyses of activity measurement (step count) at 7, 14, and 42 days post-randomisation. 1: Mean difference is estimated using a t-test. MD > 0 indicates higher mean daily steps in dressing changes with honey group. Discussion The findings of this randomised controlled trial of raw honey dressings for treating chronic neuropathic ulcers in patients with leprosy demonstrated a modestly higher healing rate in the treatment group compared to the control group (29.2% vs. 24.6% complete re-epithelialisation at 84 days), the difference was not statistically significant (adjusted HR: 1.26, 95% CI: 0.64–2.47). Similarly, ulcer recurrence and new ulcer development at six months post-randomisation were comparable between the two groups. These results suggest that while honey may offer some benefits, its superiority over normal saline dressings remains inconclusive within the context of this study. The observed trend towards improved healing with honey aligns with historical and contemporary evidence supporting honey’s wound-healing properties. Honey has been shown to promote tissue growth, facilitate debridement, and exhibit antimicrobial effects in various wound types, as highlighted by Jull et al. [14] and Subrahmanyam and Ugane [17]. However, the lack of statistical significance in our findings contrasts with some studies reporting more pronounced benefits of honey in chronic wounds, such as diabetic foot ulcers and venous leg ulcers [14]. This discrepancy may stem from differences in wound aetiology, as leprosy-related ulcers are uniquely complicated by neuropathy and reduced blood supply, factors that may attenuate the therapeutic effects of honey [1,6]. The study’s results also resonate with the broader literature on leprosy ulcer management, which underscores the challenges of achieving sustained healing in neuropathic wounds. For instance, Napit et al. [6] emphasised the recalcitrant nature of leprosy ulcers and the need for innovative treatments, though their trial focused on autologous blood products rather than honey. Similarly, Reinar et al. [7] noted the paucity of high-quality evidence for ulcer treatments in leprosy, a gap this study sought to address. Our findings contribute to this limited evidence base but highlight the need for further research to clarify honey’s role. The study’s rigorous design, prospective, randomised, and single-blinded, strengthens its internal validity. The use of standardised photographic assessment and blinded evaluators in Nepal minimised measurement bias, a common limitation in wound-healing trials [24]. However, the high dropout rate (36.2%) and relatively small sample size may have limited the study’s power to detect significant differences. The sample size calculation assumed a 70% healing rate in the control group, but the observed rate was lower (24.6%), potentially reflecting the refractory nature of leprosy ulcers in this population. Future studies with larger cohorts and longer follow-up periods are warranted to confirm or refute these findings. Despite the non-significant results, the trend favouring honey dressings suggests that this intervention may still hold promise, particularly in resource-limited settings where honey is readily available and cost-effective. The safety profile of honey, with no reported adverse events in this trial, further supports its consideration as an adjunct therapy. However, clinicians should weigh these potential benefits against the lack of definitive evidence and consider multimodal approaches, including offloading and self-care practices, as recommended by WHO guidelines [8,9,27]. The study’s limitations include its single-blinded design, which may have introduced performance bias, and the heterogeneity of ulcer characteristics at baseline. However, the step counts were similar across groups and any performance bias was clearly insufficient to yield a positive result. The follow-up period of six months may have been insufficient to capture long-term recurrence rates, but the hypothesis was related to healing, not recurrence. The use of local honey introduces variability in composition that could influence outcomes, a problem for all non-pharmacologically prepared formulations in wound care. In summary, this trial adds to the sparse literature on leprosy ulcer management but does not provide conclusive evidence for the superiority of honey over normal saline dressings. The findings underscore the complexity of treating neuropathic ulcers and the need for further high-quality studies with larger, more diverse populations to explore honey’s potential role. Until such evidence emerges, honey may be considered a safe and feasible option, though not a definitive solution, for leprosy-related ulcer care. Conclusion This randomised controlled trial represents one of the first robust evaluations of honey dressings for chronic neuropathic ulcers in leprosy patients. While the results demonstrated a modest, non-significant trend towards improved healing with honey compared to standard saline dressings, they ultimately failed to show conclusive superiority of this traditional therapy. The findings contribute valuable data to the limited evidence base for leprosy ulcer management. The study’s methodological strengths, including its randomised design, blinded outcome assessment, and standardised intervention protocol, provide a solid foundation for interpreting these results. However, the high attrition rate and relatively small sample size underscore the need for larger, multicentre trials with longer follow-up periods. Future research should explore optimal honey formulations, potential synergistic effects with other therapies, and strategies to enhance treatment adherence in this vulnerable population. From a clinical perspective, we recommend a comprehensive wound care approach in resource-limited settings where leprosy remains endemic. However, we also reinforce the importance of holistic management strategies that address the multifactorial nature of neuropathic ulcers, including pressure offloading, infection control, and patient education. The continued search for more effective interventions for leprosy-related ulcers remains a critical priority in global neglected tropical disease research. We would urge any clinicians who wish to use honey treatment offer patients entry into randomised trials with blinded outcome assessment. Supporting information Trial information sheet. Contains details of the information sheet that was handed out and explained to the participants to decide to voluntarily participate in the trial. (DOCX) Trial consent form. The detailed written informed consent document that was signed by all the participants before enrollment into the trial. (DOCX) Analysis final report. The final report prepared by the trial statisticians. (DOCX) CONSORT checklist. Checklist of items in accordance with the CONSORT guidelines (Adapted from https://journals.lww.com/asnjournals/Documents/CONSORT%202025.pdf). (PDF) 16 Oct 2025 A randomised controlled trial of raw honey for the healing of ulcers in leprosy in Nigeria PLOS Neglected Tropical Diseases Dear Dr. Tsaku, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within 60 days. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Peter Steinmann, Ph.D. Academic Editor PLOS Neglected Tropical Diseases Ana LTO Nascimento Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 Additional Editor Comments : Please carefully consider and respond to all comments, with special consideration to reviewer #2! Journal Requirements: 1) Please ensure that the CRediT author contributions listed for every co-author are completed accurately and in full. At this stage, the following Authors/Authors require contributions: Paul Alumbugu Tsaku, Sunday Odihiri Udo, Pius Ogbu Sunday, Anthony Meka, Linda Chinonso Ugwu, Abiola Oladejo, Joshua Akinyemi, Akinyinka Omigbodun, Sopna Choudhury, Jo Sartori, Onaedo Ilozumba, Samuel Watson, and Richard Lilford. Please ensure that the full contributions of each author are acknowledged in the "Add/Edit/Remove Authors" section of our submission form. The list of CRediT author contributions may be found here: https://journals.plos.org/plosntds/s/authorship#loc-author-contributions 2) Please provide an Author Summary. This should appear in your manuscript between the Abstract (if applicable) and the Introduction, and should be 150-200 words long. The aim should be to make your findings accessible to a wide audience that includes both scientists and non-scientists. Sample summaries can be found on our website under Submission Guidelines: https://journals.plos.org/plosntds/s/submission-guidelines#loc-parts-of-a-submission 3) We do not publish any copyright or trademark symbols that usually accompany proprietary names, eg ©, ®, or TM (e.g. next to drug or reagent names). Therefore please remove all instances of trademark/copyright symbols throughout the text, including: - TM on page: 10. 4) Please upload all main figures as separate Figure files in .tif or .eps format. For more information about how to convert and format your figure files please see our guidelines: https://journals.plos.org/plosntds/s/figures 5) We have noticed that you referred to supplementary materials on page 22. However, there are no corresponding files uploaded to the submission. Please upload them as separate files with the item type 'Supporting Information'. Note: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Reviewers' Comments: Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: Table 1: one of the characteristics is VMT/ST - this is the name of a test that includes many examinations, so what does normal and impaired VMT/ST mean in this context? The is a separate line for loss of sensation - so that is the ST part of 'VMT/ST. We then have 'loss of motor function' - what motor function is being tested in this context? is it only dorsi-flexion, or is it more than that? The 84 days is based on a study that used total contact casts - this study did not use TCCs, so not comparable. As this is a research study, the honey was tested in a laboratory before being used, to ensure it was not contaminated with microbes. This would not be the case if used routinely. Do the authors have any advice or caution for using honey that has not been tested for contamination? Reviewer #2: (No Response) Reviewer #3: The study's objective to test the hypothesis that raw honey improves the healing rates of leprosy-related ulcers compared to standard saline is clearly stated and testable. The dual-centre, single-blinded RCT design is appropriate, and the inclusion and exclusion criteria are well-defined. Sample size justification is reasonable, although the power is reduced due to high attrition. Statistical analyses used in the study are suitable and well interpreted. Ethical procedures are well described with all the necessary approvals and informed consent in place. ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: The results are clearly presented and supported by appropriate tables. Figures, including the CONSORT flow diagram, are clear and informative. The primary outcome shows a modest but non-significant trend favouring honey. The secondary outcomes (recurrence, new ulcers) are presented clearly and support the main finding of no significant difference. It could have been interesting to understand if any significant instructions on selfcare were provided post discharge, which had an influence on prognosis. Figures are acceptable. ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: Honey is stated as a safe, affordable option in resource-limited settings. But we are not given the cost compared to normal saline. Reviewer #2: (No Response) Reviewer #3: The conclusions are balanced and supported by the data. The authors appropriately highlight honey's potential safety and acceptability without overstating efficacy. Limitations and public health relevance are clearly discussed. ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: none Reviewer #2: (No Response) Reviewer #3: No modifications needed. It can be accepted. ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: The study repeats the importance of pressure relief for healing wounds, rather than the wound cleaning material/solution. Reviewer #2: Introduction: Para 1 - is it the pathogen itself or the immune response to that pathogen that causes nerve damage? Or both? Para 2- in the list of other things people have tried I think it should be made clearer that the evidence for benefit for ost of these interventions is very minimal. Methods The formatting of the flow diagram is poor with words spilling out of the boxes etc. Please try and correct this. Consent is not fully described - was thias written consent? Why were the specific study sites chosen? Please make clear in the methods that the trial was pre-registered (I can see this is given elsewhere but should also ideally be in the methods). Please review the CONSORT checklist for RCTs and ensure that the paper is reported in line with this. Please submit a CONSORT checklist with the paper. Please describe the intervention in more details. For example does all the honey come from a single producer? Is there inter-batch variation? What fabric material was used for both control and intervention dressings? Is the approach taken to measuring ulcer size using photos and the software validated? Is there good reproducibility? And inter-observer agreement - it seems critical some evidence for this is provided as it serves as the key outcome measure. I am unclear if the primary outcome was the proportion healed at end of follow-up OR the time to healing? Was the protocol and the SAP published in advance? What is the PRIMARY analysis - is it with or without adjustment. As currwently written the stats plan is very difficult to decide what was specified a priori and what was post-hoc. Is the primary analysis ITT or PP? This isnt stated. When someone had >1 ulcer how was the outcome ascertained? Time to healing of a specific ulcer? Of all ulcers? The trial was funded in the UK but there doesnt appear to be any ethics approval in the UK? Throughout there are averages given without measures of dispersion (i.e the mean ulcer size was X but what was the SD, is a mean the best measure or a median?) I appreciate some of these are in tables but its good practice to include in the text too. Tablr 1 is very long. I suspect this couldbe summarised with more detailed information in a supplementary table. In the results please avoid using language that suggests a positive difference when in fact there was no statistically significant differences found. for example ' " the slope of reduction was steeper in the honey-treated group, suggesting a more favourable healing trajectory. " O" With the unadjusted hazard ratio (HR) of 1.17 (95% CI: 0.60–2.27), honey had a 17% higher chance of healing compared to saline, but the confidence interval includes 1 (no effect), so this is not statistically significant." Please review all of the results thoroughly for such language. Figure 3 is incredibly hard to intrepet. Please consider a clearer visualisation. Table 3 seems to be raw Stata output - is this really needed? Dont describe sensitivity analysis methods in the results. These should be in the methods and it should be clear if these were pre-specified or post-hoc. Reviewer #3: The study is a high quality clinical trial, which is well designed, ethically sound and focuses on addressing the crucial component of ulcer management in Leprosy. Despite the results being neutral, the study contributes valuable evidence and demonstrates high research quality in the NTD settings. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy . Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols 15 Dec 2025 Submitted filename: Response to reviewers PNTDs 09.12.25.docx 17 Dec 2025 Dear Dr. Tsaku, We are pleased to inform you that your manuscript 'A randomised controlled trial of raw honey for the healing of ulcers in leprosy in Nigeria' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Peter Steinmann, Ph.D. Academic Editor PLOS Neglected Tropical Diseases Ana LTO Nascimento Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 *********************************************************** p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none Dear Dr Tsaku, We are delighted to inform you that your manuscript, "A randomised controlled trial of raw honey for the healing of ulcers in leprosy in Nigeria," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases